Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-Line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer.

Trial Profile

Randomized Phase II Study to Investigate the Efficacy, Safety and Tolerability of ZK 230211 (25 mg vs. 100 mg) as Second-Line Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Metastatic Breast Cancer.

Completed
Phase of Trial: Phase II

Latest Information Update: 14 Nov 2014

At a glance

  • Drugs Lonaprisan (Primary)
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors Bayer; Bayer HealthCare
  • Most Recent Events

    • 05 Apr 2011 Actual end date (Mar 2011) added as reported by ClinicalTrials.gov.
    • 05 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 25 Jun 2010 Planned end date changed from Jul 2011 to Apr 2011 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top